Literature DB >> 22910030

Interaction between IGF binding protein-3 and TGFβ in the regulation of adipocyte differentiation.

Hasanthi C de Silva1, Sue M Firth, Stephen M Twigg, Robert C Baxter.   

Abstract

The development of white adipose tissue involves both the hypertrophy of existing adipocytes and the proliferation and differentiation of preadipocytes. Adipogenic differentiation is inhibited by TGFβ signaling through Smad2/3, and IGF binding protein-3 (IGFBP-3) is also known to activate Smad2/3 signaling in some cell types. We previously reported that exogenous or overexpressed IGFBP-3 inhibits adipogenesis in 3T3-L1 cells, but the role of endogenous IGFBP-3 in this process, and its possible interaction with TGFβ, is not known. During 10-d adipogenic differentiation initiated by insulin, dexamethasone, and 3-isobutyl-1-methylxanthine, 3T3-L1 cells expressed increasing levels of IGFBP-3 and TGFβ1, secreting over 1000 pg/ml of both proteins. Exogenous recombinant human IGFBP-3 paralleled TGFβ1 in stimulating Smad2 phosphorylation in 3T3-L1 preadipocytes, but no additive effect was observed for the two agents. In contrast, knockdown of endogenous IGFBP-3 by small interfering RNA (siRNA) significantly impaired Smad2 activation by 0.25 ng/ml TGFβ1. Transient expression of human IGFBP-3 significantly inhibited the induction of adipogenic markers adiponectin and resistin, and the appearance of lipid droplets, but down-regulation of endogenous IGFBP-3 by siRNA had little effect on the expression of either marker during the 10-d differentiation, compared with nonsilencing control siRNA. However, down-regulation of endogenous IGFBP-3 using two different siRNA significantly reversed the inhibitory effect of TGFβ1 on both adiponectin and resistin induction. We conclude that IGFBP-3 activates inhibitory Smad signaling in 3T3-L1 cells and that endogenous IGFBP-3 modulates their adipogenic differentiation by regulating cell sensitivity towards the inhibitory effect of TGFβ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22910030     DOI: 10.1210/en.2011-1444

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Nuclear actions of insulin-like growth factor binding protein-3.

Authors:  Robert C Baxter
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

2.  CCN2 requires TGF-β signalling to regulate CCAAT/enhancer binding proteins and inhibit fat cell differentiation.

Authors:  William W C Song; Susan V McLennan; Charmaine Tam; Paul F Williams; Robert C Baxter; Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2014-10-30       Impact factor: 5.782

Review 3.  Association of Specific Genetic Polymorphisms with Atraumatic Osteonecrosis of the Femoral Head: A Narrative Review.

Authors:  Prasoon Kumar; Pratik M Rathod; Sameer Aggarwal; Sandeep Patel; Vishal Kumar; Karan Jindal
Journal:  Indian J Orthop       Date:  2022-01-06       Impact factor: 1.033

4.  Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions.

Authors:  Robert C Baxter
Journal:  J Cell Commun Signal       Date:  2013-08       Impact factor: 5.782

Review 5.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

6.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

Review 7.  Role of insulin-like growth factor binding protein-3 in glucose and lipid metabolism.

Authors:  Ho-Seong Kim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2013-03-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.